SEC Company Response from Damora Therapeutics, (DMRA) — Nov 10, 2021
Damora Therapeutics, Inc.
Date: Nov. 10, 2021 · CIK: 0001800315 · Accession: 0001564590-21-056165
AI Filing Summary & Sentiment
File numbers found in text: 333-260778
Letter
glto-corresp.htm
GALECTO, INC.
Ole Maaloes Vej 3
DK-2200 Copenhagen N
Denmark
November 10, 2021
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Galecto, Inc.: Registration Statement on Form S-3 filed November 4, 2021 (File No. 333-260778)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Galecto, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 12, 2021, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact William A. Magioncalda of Goodwin Procter LLP at (212) 459-7247.
[Remainder of Page Intentionally Left Blank]
Sincerely,
GALECTO, INC.
Show Raw Text
CORRESP 1 filename1.htm glto-corresp.htm GALECTO, INC. Ole Maaloes Vej 3 DK-2200 Copenhagen N Denmark November 10, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Galecto, Inc.: Registration Statement on Form S-3 filed November 4, 2021 (File No. 333-260778) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Galecto, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 12, 2021, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact William A. Magioncalda of Goodwin Procter LLP at (212) 459-7247. [Remainder of Page Intentionally Left Blank] Sincerely, GALECTO, INC. /s/ Jonathan Freve Name: Jonathan Freve Title: Chief Financial Officer cc: Edwin O’Connor, Esq., Goodwin Procter LLP William A. Magioncalda, Esq., Goodwin Procter LLP